Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
30.6M
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
966K
-
Shares change
-
+966K
-
Total reported value, excl. options
-
$1.81M
-
Value change
-
+$1.81M
-
Number of buys
-
28
-
Price
-
$1.87
Significant Holders of Vistagen Therapeutics, Inc. - Common Stock (VTGN) as of Q2 2023
29 filings reported holding VTGN - Vistagen Therapeutics, Inc. - Common Stock as of Q2 2023.
Vistagen Therapeutics, Inc. - Common Stock (VTGN) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 966K shares
of 30.6M outstanding shares and own 3.15% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (224K shares), GSA CAPITAL PARTNERS LLP (199K shares), BlackRock Inc. (105K shares), MILLENNIUM MANAGEMENT LLC (101K shares), GEODE CAPITAL MANAGEMENT, LLC (57.3K shares), GOLDMAN SACHS GROUP INC (57.3K shares), Y-Intercept (Hong Kong) Ltd (47.7K shares), Cubist Systematic Strategies, LLC (41.4K shares), RHUMBLINE ADVISERS (30.2K shares), and STATE STREET CORP (25.5K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.